Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3ZN5U
|
|||
| Drug Name |
Axatilamab
|
|||
| Synonyms |
SNDX-6352
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Syndax Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Macrophage colony-stimulating factor 1 receptor (CSF1R) | Target Info | Antagonist | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| Viral protein interaction with cytokine and cytokine receptor | ||||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03238027) A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Syndax Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.